---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000074"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:12:15.661079+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023

## Summary
- VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.
- Net income $80.7M ($2.79 diluted EPS) vs net loss ($29.9M) year-ago; includes $100M gain on PRV sale.
- Cash, equivalents and investments $598.6M; R&D expense $10.6M; SG&A $23.7M.
- Pipeline: Cohort 1 complete in Phase 1 KB407 (CF); first patient dosed in Phase 1 KB707 (solid tumors); IND cleared for KB408 (AATD).
- B-VEC filed for EU marketing authorization; Japan extension study dosed 5 patients; PRV sold for $100M; ASTRA facility operational.

## SEC filing metadata
- accession: 0001711279-23-000074
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/0001711279-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/krys-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000074
- JSON: https://secwatch.observer/filing/0001711279-23-000074.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000074.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported financial results for the quarter ending September 30, 2023.
  - Period: the quarter ending September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/0001711279-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.